Home > Healthcare > Medical Devices > Diagnostic Devices > Male Infertility Market

Male Infertility Market Trends

Report ID: GMI10497
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Male Infertility Market Trends

Advancements in diagnostic technologies for male infertility have revolutionized the field, offering unprecedented insights into the complexities underlying reproductive health. From enhanced semen analysis techniques to sophisticated genetic testing and AI-driven diagnostics, these innovations are reshaping how clinicians diagnose and treat male infertility.

Sperm DNA fragmentation testing assesses the integrity of sperm DNA. High levels of fragmentation can indicate sperm damage that may impair fertility or increase the risk of miscarriage. This testing provides crucial insights into male infertility beyond traditional semen analysis, allowing for targeted treatment strategies such as antioxidants or lifestyle modifications to improve sperm quality.
Advances in genetic testing, including karyotyping and Y chromosome microdeletion analysis, help identify genetic abnormalities that can contribute to infertility, providing insights for personalized treatment.
Further, imaging modalities, including scrotal ultrasound and magnetic resonance imaging (MRI), play crucial roles in diagnosing anatomical abnormalities such as varicoceles, cryptorchidism, or congenital defects that may impair sperm production or transport. These technologies aid in planning surgical interventions or medical treatments aimed at restoring fertility, thereby contributing to market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Male infertility market size was valued at USD 4 billion in 2023 and is estimated to grow at 4.7% CAGR from 2024 to 2032, driven by the rapid growth in assisted reproductive technologies.

The hospitals pharmacies segment accounted for USD 2.1 billion in 2023 and will grow rapidly through 2032, as hospital pharmacies have access to a wide range of fertility medications.

U.S male infertility market size is projected to reach USD 2.2 billion by 2032, driven by technological innovations in reproductive medicine and male infertility treatment.

Endo International plc, HalotechDNA, Intas Pharmaceuticals Ltd, Merck KGaA, Sanofi, SCSA Diagnostics, Inc, and The Cooper Companies, Inc. among others.